Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    

AMA Coalition Calls on CMS to Backtrack on Step Therapy Decision


An AMA-led coalition of 94 medical societies delivered a letter to CMS about the serious concerns physicians have with CMS' recent decision to allow Medicare Advantage plans to use step therapy for Part B drugs. The letter calls on CMS Administrator Verma to reinstate its 2012 policy prohibiting Medicare Advantage plans from utilizing step therapy protocols for Part B physician administered medications.

The letter is the latest development in the AMA's continuing effort to confront insurer hurdles on medically necessary patient care, including step therapy and prior authorization programs. The growing burdens generated by step therapy and prior authorization programs create a lengthy process of red tape, multiple phone calls and bureaucratic battles that delay and disrupt patient access to care.

For additional information, please see a recent AMA survey on physician experiences with health insurers' prior authorization programs.

September 7, 2018

The Honorable Seema Verma Administrator

Centers for Medicare & Medicaid Services

U.S. Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200 Independence Avenue, SW

Washington, DC 20201

Re: Memo of August 7th Regarding Prior Authorization and Step Therapy for Part B Drugs in Medicare Advantage

The undersigned organizations representing physicians thank the Centers for Medicare and Medicaid Services (CMS) for its attention to the negative impacts of high drug prices on Medicare and Medicaid beneficiaries, physicians, and the health care system. However, we have serious concerns about CMS's recent notification to Medicare Advantage plans that they will no longer be prohibited from utilizing step therapy protocols for physician administered drugs covered under Medicare Part B beginning in 2019.

We find the growing trend towards the use of restrictive and burdensome utilization management tactics by payors concerning and urge CMS to reconsider its stance on this critical patient care issue.

Step therapy protocols that require patients to try and fail certain treatments before allowing access to other, potentially more appropriate treatments can both harm patients and undercut the physician-patient decision-making process. The most appropriate course of treatment for a given medical condition depends on the patient's unique clinical situation and the care plan developed by the physician in close consultation with that patient. While a particular drug or therapy might be generally considered appropriate for a condition, the presence of comorbidities, potential drug-drug interactions, or patient intolerances, for example, may necessitate the selection of an alternative drug as the first course of treatment. Step therapy requirements often fail to allow for such considerations, resulting in delays in getting patients the right treatments at the right time and unnecessary complications in the physician- patient decision-making process.

While step therapy protocols are problematic for many patients on a variety of therapies, they are particularly concerning where physician-administered drugs are concerned. In many cases, patients receiving drugs covered under Part B are especially vulnerable, many with serious or life-threatening conditions. Many cancer therapies, for example, are covered under Part B. For cancer patients, selecting the proper personalized treatment as quickly as possible can be critical to survival. For others, such as those suffering from conditions like autoimmune disorders and progressive blinding eye diseases, delays in getting appropriate treatments can mean prolonged symptomatic periods and irreversible damage, making a "fail first" approach to treatment inappropriate. Although the notification states that step therapy can only be applied to new prescriptions and administrations of Part B drugs, we have serious concerns about patients who will change Medicare Advantage plans being required to disrupt their current treatment to retry previously failed therapeutic regimens to meet step therapy requirements for a new plan. We also note that many Part B drugs are periodically infused, compared to being administered on a routine basis, which could easily lead to different interpretations between plans in what is considered a "newly prescribed" medication and to interruptions in ongoing therapy that could have devastating, permanent consequences for Medicare beneficiaries and their health.

Step therapy likewise places a significant administrative burden on physician practices. Physicians do not currently have ready access to patient benefit and formulary information, as there is currently no capability making this information available through electronic health records or other means at the point of prescribing. This lack of transparency makes it exceedingly difficult to determine what treatments are preferred by a particular payor at the point of care and places practices at financial risk for the cost of administered drugs if claims are later denied for unmet (yet unknown) step therapy requirements.

Furthermore, payor exemption and appeals processes can be complicated and lengthy, making them burdensome for both busy physician practices and patients awaiting treatment. At a time when CMS has prioritized regulatory burden reduction in the patient-provider relationship through its Patients Over Paperwork initiative, it is our hope that another layer of administrative complication will not be added on to an already strained system.

As rising drug prices continue to place huge financial burdens on patients and the health care system, we recognize the significant difficulty of finding meaningful solutions that have the desired outcome of reducing costs for both. However, as we work towards finding policies to address this problem, we hope that solutions can be found that do not involve the creation of barriers to appropriate and timely treatment for some of our most critical patients. Given this, we urge CMS to reinstate its 2012 policy prohibiting Medicare Advantage plans from utilizing step therapy protocols for Part B physician administered medications. We look forward to working with CMS to find a better path forward for physicians and patients.


American Medical Association

American Academy of Allergy, Asthma & Immunology American Academy of Dermatology Association

American Academy of Facial Plastic and Reconstructive Surgery American Academy of Hospice and Palliative Medicine American Academy of Neurology

American Academy of Ophthalmology American Academy of Otolaryngic Allergy/Foundation

American Academy of Pain Medicine

American Academy of Physical Medicine and Rehabilitation American Association for Hand Surgery

American Association of Clinical Endocrinologists American Association of Neurological Surgeons

American College of Allergy, Asthma and Immunology and the Advocacy Council American College of Cardiology

American College of Gastroenterology American College of Obstetricians and Gynecologists

American College of Osteopathic Internists American College of Osteopathic Surgeons American College of Physicians

American College of Rheumatology American Epilepsy Society

American Gastroenterological Association American Glaucoma Society

American Medical Women's Association

American Orthopaedic Foot & Ankle Society American Psychiatric Association

American Society for Gastrointestinal Endoscopy American Society for Metabolic and Bariatric Surgery American Society for Radiation Oncology

American Society for Surgery of the Hand American Society of Cataract & Refractive Surgery American Society of Clinical Oncology

American Society of Hematology American Society of Plastic Surgeons American Society of Retina Specialists American Society of Transplant Surgeons American Urological Association College of American Pathologists Congress of Neurological Surgeons

Heart Rhythm Society

Medical Group Management Association

Society for Cardiovascular Angiography and Interventions Society of Critical Care Medicine

Society of Gynecologic Oncology

Medical Association of the State of Alabama Alaska State Medical Association

Arizona Medical Association Arkansas Medical Society California Medical Association Colorado Medical Society Connecticut State Medical Society Medical Society of Delaware

Medical Society of the District of Columbia Florida Medical Association Inc Medical Association of Georgia

Hawaii Medical Association Idaho Medical Association Illinois State Medical Society Iowa Medical Society Kansas Medical Society

Kentucky Medical Association Louisiana State Medical Society Maine Medical Association

MedChi, The Maryland State Medical Society Massachusetts Medical Society Michigan State Medical Society Minnesota Medical Association

Mississippi State Medical Association Missouri State Medical Association Montana Medical Association Nebraska Medical Association

Nevada State Medical Association New Hampshire Medical Society Medical Society of New Jersey New Mexico Medical Society

Medical Society of the State of New York North Carolina Medical Society

North Dakota Medical Association Ohio State Medical Association Oklahoma State Medical Association Oregon Medical Association Pennsylvania Medical Society

South Carolina Medical Association South Dakota State Medical Association Tennessee Medical Association

Texas Medical Association Utah Medical Association Vermont Medical Society Medical Society of Virginia

Washington State Medical Association West Virginia State Medical Association Wisconsin Medical Society

Wyoming Medical Society


Related Articles:

Recent Articles

AMA Issues Checklist for the Transition to E/M Office Visit Changes

The American Medical Association (AMA) is helping physician practices integrate fundamental changes to the coding and documentation of evaluation and management (E/M) office visit services that account for nearly $23 billion in Medicare spending.

Read More

AHA's Maryjane Wurth To Retire In 2020; Michelle Hood To Join The Association

Maryjane Wurth, the American Hospital Association's (AHA) executive vice president and chief operating officer (COO), will retire next year after a long and distinguished career in the hospital association field.

Read More

Tennessee Sees Fewer Infant Deaths In 2018

Infant Mortality Data Dashboard Now Available

Read More

Amedisys Expanding Commitment to End-of-Life Care for Veterans

Third Largest Hospice Provider Cared for 5,540 Dying Veterans Last Year

Read More

AMA Applauds Relief from Documentation Burden in New Medicare Rule

Many physicians will have reduced documentation beginning in 2021

Read More

Oncology Innovation in Nashville

From personalized medicine to innovation in GI care, Middle Tennessee oncology leaders share promising news.

Read More

Critical Insights into Nashville Health

For the first time in nearly two decades, Nashville has a countywide assessment providing insights into the health and well-being of the community.

Read More

Physician Spotlight: Leading with Compassion

Hospice care is so much more than simply pain management. Compassus CMO Dr. Kurt Merkelz focuses on helping patients live fully until the end.

Read More

The Oncology Care Model Value Proposition

The American Journal of Managed Care® hosts meetings across the country to help oncology practices understand and navigate the value-based care landscape at the intersection of quality and efficiency.

Read More

Tennessee Falling Short on Cancer-Fighting Public Policies

A 2019 ACS CAN report shows the state is falling short on public policies to fight cancer.

Read More

Email Print



AMA, American Medical Association, Centers for Medicare & Medicaid Services, CMS
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: